Lexapro (Escitalopram) for Depression: Dosing, Duration, and Monitoring
Start escitalopram at 10 mg once daily, which is both the initial and recommended dose for most adults with major depressive disorder. 1
Starting Dose and Titration
Begin with 10 mg once daily, taken either morning or evening, with or without food. 1 This dose is effective for moderate depression and serves as the therapeutic target for most patients 2.
- For moderate depression (MADRS 22-29): 10 mg daily is optimal and shows clinical response within 2 weeks 2
- For severe depression (MADRS ≥30): Consider increasing to 20 mg daily after initial trial, as this dose shows superior efficacy in severe cases 2
- Maximum dose: 20 mg once daily 1
Important dosing exceptions:
- Elderly patients: Limit to 10 mg daily (do not increase) 1
- Hepatic impairment: Limit to 10 mg daily 1
- Adolescents 12-17 years: Start at 10 mg daily; maximum 20 mg daily 1
The evidence shows no additional benefit from 20 mg over 10 mg in moderate depression, but 20 mg is necessary for severe presentations 1, 2. One high-quality study demonstrated that dose escalation to 30 mg in non-remitters after standard dosing showed modest additional benefit, though this exceeds FDA-approved dosing 3.
Assessment of Response and When to Modify Treatment
Monitor patients within 1-2 weeks of starting treatment, focusing specifically on suicidal ideation, agitation, irritability, and unusual behavioral changes. 4 The risk for suicide attempts is highest during the first 1-2 months of treatment 4.
Timeline for Expected Response:
- Week 2: Expect onset of effect (≥20% symptom reduction). If no improvement by week 2, the probability of eventual response drops significantly 5
- Week 4: If no response by this point, the chance of responding by week 8 is only 20% or less 5
- Week 6-8: Modify treatment if inadequate response by 6-8 weeks 4
The evidence is clear: if a patient shows no improvement whatsoever by week 2, their likelihood of responding to continued treatment at the same dose is only 43%, compared to nearly 80% in those showing early onset of effect 5. This supports early intervention rather than prolonged trials at ineffective doses.
Duration of Treatment
Continue treatment for 4-9 months after achieving satisfactory response in first-episode depression. 4
Specific Duration Guidelines:
- First episode of MDD: 4-9 months after remission to prevent relapse 4
- Two or more prior episodes: Consider years to lifelong treatment 4
- Recurrent depression: Extended maintenance therapy is beneficial 4
The distinction between relapse (during continuation phase, 4-9 months) and recurrence (during maintenance phase, beyond 9 months) is clinically important. Patients achieving remission with acute treatment require continuation therapy to consolidate gains 4.
Discontinuation Strategy
When stopping escitalopram, taper gradually rather than abrupt cessation. 1 While escitalopram has a relatively lower risk of discontinuation syndrome compared to shorter-acting SSRIs like paroxetine 6, gradual dose reduction minimizes withdrawal symptoms including dizziness, fatigue, sensory disturbances, and anxiety 6.
Monitoring Plan
Initial Phase (Weeks 1-8):
- Week 1-2: Assess for suicidal ideation, agitation, behavioral changes, and early adverse effects 4
- Week 2: Evaluate for onset of therapeutic effect (≥20% improvement) 5
- Week 4: Reassess response; consider intervention if no improvement 5
- Week 6-8: Definitive assessment of response; modify treatment if inadequate 4
Continuation Phase (Months 2-9):
- Regular monitoring for sustained response and adverse effects
- Assess for relapse symptoms
Common Adverse Effects to Monitor:
Most frequent side effects (≥5% incidence) include insomnia, ejaculatory delay, nausea, increased sweating, fatigue, somnolence, decreased libido, and anorgasmia 1. Patients with pretreatment anxious depression (GAD-7 ≥10) experience significantly more side effects, particularly nervousness and agitation, in the first 2 weeks 7.
Critical Safety Considerations
Screen for bipolar disorder before initiating treatment, as SSRIs can precipitate manic episodes. 1 Monitor for hyponatremia, particularly in elderly patients and those on diuretics 1. Avoid combining with MAOIs (14-day washout required), pimozide, or other serotonergic agents due to serotonin syndrome risk 1.
Escitalopram has the lowest propensity for drug-drug interactions among SSRIs due to minimal effects on cytochrome P450 enzymes 6, making it particularly suitable for patients on multiple medications.
Selection Rationale
While all second-generation antidepressants show equivalent efficacy 4, select escitalopram based on its favorable adverse effect profile, once-daily dosing, low drug interaction potential, and patient preference 4. The evidence does not support choosing one SSRI over another based solely on efficacy, as response rates are similar across agents (approximately 50%) 4.